Significance of FDA Database Listing and Pipeline Management

Verity Pharmaceuticals' prostate cancer treatment, Trelstar (triptorelin pamoate), has been officially listed in the U.S. FDA's NDA (New Drug Application) database. This regulatory information listing demonstrates that Verity Pharmaceuticals, which acquired exclusive U.S. commercialization rights for 20 years from Debiopharm in 2020, is steadily managing the product lifecycle as the regulatory management entity. Transparent and up-to-date approval status is a prerequisite for establishing distribution partnerships and inclusion in hospital formularies within the U.S. This update can be seen as an essential administrative procedure that lays the foundation for continuously supplying stable treatments to patients in the U.S. market.

Therapeutic Role and Mechanism in Androgen Deprivation Therapy

Trelstar is a GnRH (gonadotropin-releasing hormone) receptor agonist that suppresses testosterone levels in the body, thereby inhibiting the growth of prostate cancer cells. The confirmed NDA 021288 approval information includes the 11.25mg depot formulation, which can be administered every three months, significantly improving patient convenience. It has been firmly established as a standard treatment for androgen deprivation therapy (ADT) for hormone-dependent progressive prostate cancer. The extended dosing interval significantly reduces the number of hospital visits for patients, improves medication adherence, and ultimately reduces healthcare costs. This offers significant clinical advantages.

Market Landscape and Competitive Analysis with Other Drugs

The global GnRH agonist market is projected to grow steadily from USD 4.19 billion in 2025 to USD 4.73 billion in 2030. Trelstar directly competes with existing GnRH agonist products such as Lupron (leuprolide) and Zoladex (goserelin) in the market. In addition, the challenge from Orgovyx (relugolix), an oral GnRH antagonist with no initial testosterone surge and convenient administration, is also intensifying. In response, Verity Pharmaceuticals is maintaining its competitive advantage by leveraging the inherent advantages of injectable formulations, ensuring reliable dosing management, and securing stable insurance coverage.

Long-Term Value Creation and Biopharma Investment Prospects

In an environment where the overall prostate cancer treatment market is expected to grow rapidly to approximately USD 25 billion by 2035, Trelstar is steadily fulfilling its role as a strong cash cow for Verity Pharmaceuticals. The long-term accumulation of clinical and prescription data since its initial FDA approval in 2001 supports the product's reliability and will also be advantageous when expanding indications through combination therapies in the future. Maintaining stable regulatory listings strengthens the company's long-term financial structure and will be a valuable driving force for pursuing new pipeline introductions or technology collaborations in the future.